Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis

Respiratory Medicine

Volumn 128, Issue , 2017, Pages 1-6

  Suarez Cuartin, Guillermo ^a,b   Smith, Alex ^c   Abo Leyah, Hani ^c   Rodrigo Troyano, Ana ^a,b   Perea, Lidia ^b   Vidal, Silvia ^b   Plaza, Vicente ^a,b   Fardon, Thomas C ^c   Sibila, Oriol ^a,b   Chalmers, James D ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Antibody; Bronchiectasis; Chronic infection; Pseudomonas aeruginosa

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; ANTIBODY;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CHRONIC AIRWAY INFECTION; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; BLOOD; CYSTIC FIBROSIS; EPIDEMIOLOGY; FORCED EXPIRATORY VOLUME; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTION; SEVERITY OF ILLNESS INDEX; SPUTUM; UNITED KINGDOM; VITAL CAPACITY;

AGED; ANTIBODIES; BRONCHIECTASIS; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; SPUTUM; UNITED KINGDOM; VITAL CAPACITY;

EID: 85018756587     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2017.05.001     Document Type: Article

References (36)

1. [1] Pasteur, M.C., Bilton, D., Hill, a.T., British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65 (2010), i1–i58.
2. [2] Cole, P.J., Inflammation: a two-edged sword–the model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 147 (1986), 6–15.
3. [3] Davies, G., Wells, a.U., Doffman, S., Watanabe, S., Wilson, R., The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur. Respir. J. 28 (2006), 974–979.
4. [4] King, P.T., Holdsworth, S.R., Freezer, N.J., Villanueva, E., Holmes, P.W., Microbiologic follow-up study in adult bronchiectasis. Respir. Med. 101 (2007), 1633–1638.
5. [5] McDonnell, M.J., Jary, H.R., Perry, A., MacFarlane, J.G., Hester, K.L.M., Small, T., Molyneux, C., Perry, J.D., Walton, K.E., De Soyza, A., Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir. Med. 109 (2015), 716–726.
6. [6] Finch, S., McDonnell, M.J., Abo-Leyah, H., Aliberti, S., Chalmers, J.D., A comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 12 (2015), 1602–1611.
7. [7] Chalmers, J.D., Smith, M.P., McHugh, B.J., Doherty, C., Govan, J.R., Hill, A.T., Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 186 (2012), 657–665.
8. [8] Pressler, T., Bohmova, C., Conway, S., Dumcius, S., Hjelte, L., Høiby, N., Kollberg, H., Tümmler, B., Vavrova, V., Chronic Pseudomonas aeruginosa infection definition: EuroCareCF working group report. J. Cyst. Fibros. 10 (2011), S75–S78.
9. [9] Yankaskas, J.R., Marshall, B.C., Sufian, B., Simon, R.H., Rodman, D., Cystic fibrosis adult care: consensus conference report. Chest 125 (2004), 1S–39S.
10. [10] Hill, A.T., Routh, C., Welham, S., National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care?. Thorax 69 (2014), 292–294.
11. [11] Aliberti, S., Hill, A.T., Mantero, M., Battaglia, S., Centanni, S., Cicero, S. Lo, Lacedonia, D., Saetta, M., Chalmers, J.D., Blasi, F., SIP Bronchiectasis Audit Working Group F, Roux, A. de, Diel, R., Quint, J., Millett, E., Joshi, M., Chalmers, J., Aliberti, S., Blasi, F., Pasteur, M., Bilton, D., Hill, A., Hill, A., Bilton, D., Brown, J., Hill, A., Routh, C., Welham, S., Chalmers, J., Goeminne, P., et al. Quality standards for the management of bronchiectasis in Italy: a national audit. Eur. Respir. J. 46 (2016), i1–i58.
12. [12] Pressler, T., Karpati, F., Granström, M., Knudsen, P.K., Anders, L., Lena, H., Olesen, H.V., Meyer, P., Høiby, N., Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J. Cyst. Fibros. 8 (2009), 37–42.
13. [13] Mauch, R.M., Levy, C.E., Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review. J. Cyst. Fibros. 13 (2014), 499–507.
14. [14] Li, Z., Kosorok, M.R., Farrell, P.M., Laxova, A., West, S.E.H., Green, C.G., Collins, J., Rock, M.J., Splaingard, M.L., Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293 (2005), 581–588.
15. [15] Chalmers, J.D., Goeminne, P., Aliberti, S., McDonnell, M.J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L.J., Fardon, T.C., De Soyza, A., Hill, A.T., The bronchiectasis severity index an international derivation and validation study. Am. J. Respir. Crit. Care Med. 189 (2014), 576–585.
16. [16] Martínez-García, M.a., De Gracia, J., Relat, M.V., Girón, R.M., Carro, L.M., De La Rosa Carrillo, D., Olveira, C., Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur. Respir. J. 43 (2014), 1357–1367.
17. [17] Murray, P.R., Washington, J.A., Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin. Proc. 50 (1975), 339–344.
18. [18] Pasteur, M.C., Helliwell, S.M., Houghton, S.J., Webb, S.C., Foweraker, J.E., Coulden, R.A., Flower, C.D., Bilton, D., Keogan, M.T., An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 162 (2000), 1277–1284.
19. [19] Lee, T.W.R., Brownlee, K.G., Conway, S.P., Denton, M., Littlewood, J.M., Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2 (2003), 29–34.
20. [20] Pedersen, S.S., Espersen, F., Høiby, N., Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 25 (1987), 1830–1836.
21. [21] Johansen, H.K., Nørregaard, L., Gøtzsche, P.C., Pressler, T., Koch, C., Høiby, N., Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?–A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr. Pulmonol. 37 (2004), 427–432.
22. [22] Sibila, O., Suarez-Cuartin, G., Rodrigo-Troyano, A., Fardon, T.C., Finch, S., Mateus, E.F., Garcia-Bellmunt, L., Castillo, D., Vidal, S., Sanchez-Reus, F., Restrepo, M.I., Chalmers, J.D., Secreted mucins and airway bacterial colonization in non-CF bronchiectasis. Respirology 20 (2015), 1082–1088.
23. [23] Martínez-García, M.A., Soler-Cataluña, J.-J., Perpiñá-Tordera, M., Román-Sánchez, P., Soriano, J., Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132 (2007), 1565–1572.
24. [24] Evans, S.A., Turner, S.M., Bosch, B.J., Hardy, C.C., Woodhead, M.A., Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur. Respir. J. 9 (1996), 1601–1604.
25. [25] Aliberti, S., Lonni, S., Dore, S., McDonnell, M.J., Goeminne, P.C., Dimakou, K., Fardon, T.C., Rutherford, R., Pesci, A., Restrepo, M.I., Sotgiu, G., Chalmers, J.D., Clinical phenotypes in adult patients with bronchiectasis. Eur. Respir. J. 47 (2016), 1113–1122.
26. [26] Caballero, E., Drobnic, M.-E., Pérez, M.-T., Manresa, J.-M., Ferrer, A., Orriols, R., Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis. Thorax 56 (2001), 669–674.
27. [27] Haworth, C.S., Foweraker, J.E., Wilkinson, P., Kenyon, R.F., Bilton, D., Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 189 (2014), 975–982.
28. [28] Barker, A.F., O'Donnell, A.E., Flume, P., Thompson, P.J., Ruzi, J.D., de Gracia, J., Boersma, W.G., De Soyza, A., Shao, L., Zhang, J., Haas, L., Lewis, S.A., Leitzinger, S., Montgomery, A.B., McKevitt, M.T., Gossage, D., Quittner, A.L., O'Riordan, T.G., Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet. Respir. Med. 2 (2014), 738–749.
29. [29] Murray, M.P., Govan, J.R.W., Doherty, C.J., Simpson, a.J., Wilkinson, T.S., Chalmers, J.D., Greening, A.P., Haslett, C., Hill, A.T., A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 183 (2011), 491–499.
30. [30] Vidya, P., Smith, L., Beaudoin, T., Yau, Y.C., Clark, S., Coburn, B., Guttman, D.S., Hwang, D.M., Waters, V., Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 35 (2016), 67–74.
31. [31] Kenny, S.L., Shaw, T.D., Downey, D.G., Moore, J.E., Rendall, J.C., Elborn, J.S., Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis. BMJ open Respir. Res., 1, 2014, e000021.
32. [32] Cohen-Cymberknoh, M., Gilead, N., Gartner, S., Rovira, S., Blau, H., Mussaffi, H., Rivlin, J., Gur, M., Shteinberg, M., Bentur, L., Livnat, G., Aviram, M., Picard, E., Tenenbaum, A., Armoni, S., Breuer, O., Shoseyov, D., Kerem, E., Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis. J. Cyst. Fibros., 2016, 10.1016/j.jcf.2016.04.006 pii: S1569–1993(16)30023-6, (Epub ahead of print).
33. [33] Barker, A.F., Couch, L., Fiel, S.B., Gotfried, M.H., Ilowite, J., Meyer, K.C., O'Donnell, A., Sahn, S.A., Smith, L.J., Stewart, J.O., Abuan, T., Tully, H., Van Dalfsen, J., Wells, C.D., Quan, J., Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 162 (2000), 481–485.
34. [34] Scheinberg, P., Shore, E., A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 127 (2005), 1420–1426.
35. [35] White, L., Mirrani, G., Grover, M., Rollason, J., Malin, A., Suntharalingam, J., Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir. Med. 106 (2012), 356–360.
36. [36] Orriols, R., Hernando, R., Ferrer, A., Terradas, S., Montoro, B., Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiration 90 (2015), 290–305.